Fill out the form to download your copy and see the results.

Using Artificial Intelligence Platforms to Enhance Study Design in Schizophrenia Trials

 

In this poster you will learn: 

  • Remote patient monitoring is critical in ensuring optimal drug exposure. Between 30-50% of CNS trials fail because patients are not following the assigned protocol.
  • It is estimated that non-adherence based on pharmacokinetic (PK) data is as high as 39% in schizophrenia trials.
  • An AI platform (AiCure®) was used to monitor adherence to study treatment in six schizophrenia studies, three completed and three ongoing. The AI platform uses software algorithms on smartphones to visually and automatically confirm medication ingestion.
  • Taking a multi-pronged approach to patient monitoring has the ability to increase drug exposure, data quality, and reduce fraud.
  • The following questions were investigated: What is the impact of an AI-driven monitoring and intervention platform on adherence and retention in schizophrenia studies?
  • How accurate are the adherence data logged by the AI Platform compared to the compliance rate as measured by pharmacokinetic data?
  • Can the adherence data collected during a lead-in period be used as an accurate predictor of adherence post-randomization?
  • Can the AI Platform be used to detect subject fraud?